Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on ARTIVA BIOTHERAPEUTICS stock.
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company developing NK cell–based therapies for autoimmune diseases and cancers. This news page aggregates company-issued updates and third-party coverage so readers can follow how Artiva’s AlloNK program and broader pipeline progress over time.
Artiva’s announcements frequently focus on AlloNK (AB-101), an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. News items describe clinical data from Phase 1 and 2 trials in B-cell driven autoimmune diseases such as refractory rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis, including safety, tolerability and translational findings.
Investors and followers of ARTV can use this feed to track key corporate developments, including FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis, selection of RA as the lead indication, enrollment progress across company-sponsored and investigator-initiated trials, and participation in healthcare and investor conferences. Financial results releases provide additional context on research and development spending, cash runway and other operating metrics, as reported in Artiva’s quarterly updates.
Coverage may also reference Artiva’s CAR-NK pipeline targeting solid and hematologic cancers, its strategic relationship with GC Cell for NK cell manufacturing technology, and governance or equity incentive plan updates disclosed through SEC filings. By reviewing the latest ARTV news, readers can follow how Artiva’s NK cell therapy programs evolve, how clinical data mature, and how the company communicates its strategy for addressing unmet needs in autoimmune disease and oncology.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 5, 2025, at 2:30 p.m. EST in Boston, MA.
The management team will be available for in-person meetings with registered conference attendees. A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section on Artivabio.com, with the replay remaining available for 90 days after the event.
Artiva Biotherapeutics (ARTV) has appointed Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker, currently interim Chief Development Officer at Cue Biopharma, brings over 20 years of pharmaceutical industry experience, including a 19-year tenure at Johnson & Johnson where he led the development of major immunology drugs like Remicade, Simponi, and Stelara, which achieved over $20 billion in peak sales.
Previously, Dr. Baker served as CEO and Founder of Kira Biotech and Executive Director on Galapagos Therapeutics' board. He holds a B.A. in Biology from Gettysburg College and an M.D. from the University of Pennsylvania, with extensive medical training and academic experience in Rheumatology.
Artiva Biotherapeutics (ARTV) reported Q3 2024 financial results, highlighting a strong cash position of $199.6 million as of September 30, 2024, expected to fund operations through 2026. The company completed an upsized $179.0 million IPO in July 2024. Q3 showed a net loss of $17.5 million compared to net income of $11.3 million in Q3 2023. R&D expenses were $13.5 million, while G&A expenses increased to $4.8 million. The company expanded its Board with Dr. Alison Moore and expects initial data for AlloNK® in autoimmune indications in H1 2025.
Artiva Biotherapeutics (Nasdaq: ARTV) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 20, 2024, at 3:30 p.m. GMT in London. The clinical-stage biotechnology company, focused on developing cell therapies for autoimmune diseases and cancers, will make the session available via live webcast through their website's Investor section. Management team members will also conduct in-person meetings with registered conference attendees. A replay of the webcast will remain accessible for 90 days post-event.
Artiva Biotherapeutics (Nasdaq: ARTV) has appointed Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, with expertise in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. and was formerly CTO of Allogene Therapeutics.
Fred Aslan, M.D., CEO of Artiva, highlighted Dr. Moore's extensive experience in manufacturing and technical operations, particularly in allogeneic cell therapies. The company believes its manufacturing process for AlloNK® sets it apart from peers, potentially accelerating the path to bring this experimental therapy to patients with autoimmune diseases and cancers.
Dr. Moore expressed enthusiasm for AlloNK®'s scalable and robust manufacturing process, noting its simplified approach due to the lack of genetic engineering. She aims to help realize the full potential of AlloNK® in treating autoimmune diseases and cancer.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. The company's management will engage in a fireside chat on September 18, 2024, at 8:00 a.m. ET in New York City.
Investors and the public can access a live webcast of the chat through the 'Investors' section on Artivabio.com. A replay will be available for 90 days after the event. Additionally, Artiva's management team will be available for in-person investor meetings during the conference.
Artiva Biotherapeutics (Nasdaq: ARTV) reported Q2 2024 financial results and recent business highlights. Key points include:
- Successful completion of a $179.0 million upsized IPO, extending cash runway through 2026
- Initiation of an investigator-initiated basket trial exploring AlloNK® in multiple autoimmune indications
- Treatment of the first patient in a Phase 1/1b trial for lupus nephritis (LN) and systemic lupus erythematosus (SLE)
- Q2 2024 financial results: $46.6 million in cash and investments (pre-IPO), $12.3 million in R&D expenses, and a net loss of $17.8 million
Artiva aims to report initial data on autoimmune indications from ongoing trials in the first half of 2025.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotechnology company, announced the pricing of its upsized initial public offering (IPO) of 13,920,000 shares of common stock at $12.00 per share. This offering is expected to yield gross proceeds of approximately $167.0 million, before underwriting discounts and offering expenses. Additionally, underwriters have a 30-day option to purchase up to 2,088,000 additional shares at the IPO price. Shares will begin trading on Nasdaq under “ARTV” on July 19, 2024, with the offering closing on July 22, 2024, pending customary conditions. Jefferies, TD Cowen, and Cantor are joint book-running managers, with Wedbush PacGrow and Needham & Company as co-lead managers.